MA38544A1 - Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques - Google Patents

Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques

Info

Publication number
MA38544A1
MA38544A1 MA38544A MA38544A MA38544A1 MA 38544 A1 MA38544 A1 MA 38544A1 MA 38544 A MA38544 A MA 38544A MA 38544 A MA38544 A MA 38544A MA 38544 A1 MA38544 A1 MA 38544A1
Authority
MA
Morocco
Prior art keywords
diethylene glycol
monoethyl ether
alkyl derivatives
pharmaceutical compositions
active pharmaceutical
Prior art date
Application number
MA38544A
Other languages
English (en)
Inventor
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Madhavlal Glovindlal Patel
Original Assignee
Themis Medicare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51263451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38544(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Themis Medicare Ltd filed Critical Themis Medicare Ltd
Publication of MA38544A1 publication Critical patent/MA38544A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques de divers principes pharmaceutiques actifs, en particulier de principes actifs lipophiles et hydrophiles, contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques de celui-ci en tant que véhicule primaire et/ou sur des compositions pharmaceutiques utilisant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques de celui-ci en tant que véhicule primaire ou en tant que système solvant dans la préparation de telles compositions pharmaceutiques. Les compositions pharmaceutiques selon la présente invention sont sans danger, elles sont non toxiques, elles présentent une stabilité physique accrue par comparaison avec des formulations classiques contenant de tels principes pharmaceutiques actifs et elles sont appropriées pour être utilisées comme préparations injectables pour administration intraveineuse et intramusculaire, ainsi que pour être utilisées sous forme de solution/liquide préformé destiné à garnir et préparer des capsules, des comprimés, des pulvérisations nasales, des gargarismes, des applications cutanées, des gels, des produits topiques, des formes pharmaceutiques liquides à usage oral et d'autres formes pharmaceutiques.
MA38544A 2013-04-02 2014-04-02 Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques MA38544A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2014/000207 WO2014178065A1 (fr) 2013-04-02 2014-04-02 Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques
IN1287MU2013 IN2013MU01287A (fr) 2013-04-02 2014-04-02

Publications (1)

Publication Number Publication Date
MA38544A1 true MA38544A1 (fr) 2017-03-31

Family

ID=51263451

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38544A MA38544A1 (fr) 2013-04-02 2014-04-02 Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques

Country Status (17)

Country Link
US (2) US9827315B2 (fr)
JP (1) JP6272454B2 (fr)
KR (2) KR101875263B1 (fr)
CN (1) CN105392469A (fr)
AU (1) AU2014261009B2 (fr)
BR (1) BR112015025172A2 (fr)
CA (1) CA2908571C (fr)
HK (1) HK1222549A1 (fr)
IN (1) IN2013MU01287A (fr)
MA (1) MA38544A1 (fr)
MX (1) MX2015013785A (fr)
PE (1) PE20151663A1 (fr)
PH (1) PH12015502290B1 (fr)
SA (1) SA515361262B1 (fr)
SG (1) SG11201508006SA (fr)
UA (1) UA119324C2 (fr)
WO (1) WO2014178065A1 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
CN104546775B (zh) * 2015-02-03 2017-08-25 山东新时代药业有限公司 一种阿托伐他汀钙片剂
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
WO2017002030A1 (fr) * 2015-06-30 2017-01-05 Leiutis Pharmaceuticals Pvt Ltd Formulations liquides stables de melphalan
JP2018530597A (ja) * 2015-10-13 2018-10-18 テミス メディケア リミティド フルベストラント組成物
KR101634382B1 (ko) * 2015-10-20 2016-06-28 미래제약 주식회사 타다라필 경구용 액제
US9463183B1 (en) * 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2017077425A1 (fr) * 2015-11-07 2017-05-11 Ftf Pharma Private Limited Solution orale à base d'inhibiteurs d'ace
EP3407875A4 (fr) * 2016-01-29 2019-09-04 Cuda Anesthetics, LLC Formulation pharmaceutique aqueuse comprenant du propofol
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
BR112018070960A2 (pt) * 2016-04-13 2019-01-29 Nortic Holdings Inc. formulação parenteral de nimodipina estável
US10092553B2 (en) 2016-04-13 2018-10-09 Nortic Holdings Inc. Stable nimodipine parenteral formulation
AU2017260327B2 (en) * 2016-05-06 2018-12-20 Harrow Ip, Llc Pharmaceutical Ophthalmic compositions and methods for fabricating thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
ES3037596T3 (en) * 2016-06-28 2025-10-03 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
EP3509592A4 (fr) 2016-09-09 2020-07-22 Cutispharma, Inc. Suspensions et diluants pour le métronidazole et le baclofène
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
BE1024559B1 (nl) * 2017-02-21 2018-04-05 Purna Pharmaceuticals Nv Werkwijze voor het maken van een verstuifbare emulsie omvattende een corticosteroïde, een aminoglycoside en een zuur
CN108721209A (zh) * 2017-04-20 2018-11-02 广东东阳光药业有限公司 一种兽用阿奇霉素注射剂
ES2982668T3 (es) * 2017-06-02 2024-10-17 Xeris Pharmaceuticals Inc Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
ES2984268T3 (es) * 2017-08-09 2024-10-29 Dechra Veterinary Products Llc Formulaciones terapéuticas que comprenden un inhibidor de la COX-2 y usos de las mismas
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
WO2019182745A1 (fr) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Formulations pour la pulvérisation d'épinéphrine
CN110314158A (zh) * 2018-03-22 2019-10-11 深圳澳美制药技术开发有限公司 噻康唑组合物及其制备方法
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
JP7492918B2 (ja) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
CN109364021A (zh) * 2018-10-26 2019-02-22 山西普德药业有限公司 一种注射用长春西汀
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2020247627A1 (fr) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Formulations à libération modifiée et utilisations associées
EP3982927A1 (fr) 2019-06-14 2022-04-20 Propella Therapeutics, Inc. Formulations d'acyclovir topique et leurs utilisations
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
US11135208B2 (en) * 2019-08-12 2021-10-05 American Regent, Inc. 1,4-dihydropyridine compositions, methods of making and use
EP4233854A3 (fr) * 2019-11-01 2024-01-17 Piedmont Animal Health Inc. Formulations thérapeutiques et leurs utilisations
MX2022007392A (es) * 2019-12-16 2022-07-27 Themis Medicare Ltd Composicion farmaceutica de inhibidores de la ciclooxigenasa 2.
CN111632029B (zh) * 2020-06-28 2021-05-07 江苏吴中医药集团有限公司 一种美索巴莫注射液及其制备方法
CA3192530A1 (fr) * 2020-09-21 2022-03-24 Xiaoming Chen Formulation pharmaceutique aqueuse de phosphate de sodium d'hydrocortisone et de monothioglycerol
EP4255393B1 (fr) 2020-12-04 2025-05-28 Arcutis Biotherapeutics, Inc. Formulation topique de roflumilast présentant des propriétés antifongiques
CN112315905B (zh) * 2020-12-07 2021-11-30 安徽海洋药业有限公司 一种蒿甲醚注射液及其制备方法
CN112370422B (zh) * 2020-12-09 2023-03-03 南京联智医药科技有限公司 取代的β-环糊精稳定的盐酸屈他维林注射液及其制备方法
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN113004301B (zh) * 2021-03-11 2022-02-18 广西师范大学 一种青蒿琥酯基-二苯基脲衍生物ars-dpu及其制备方法与应用
CN113069527B (zh) * 2021-04-20 2022-03-18 北京华睿鼎信科技有限公司 一种具有解酒保肝功能的组合物及其制备方法
CN115252801B (zh) * 2021-04-29 2025-07-08 苏州裕泰医药科技有限公司 多西他赛-油酸甘油三酯前药及脂质制剂的制备
CN115702936A (zh) * 2021-08-13 2023-02-17 杭州中美华东制药有限公司 一种芦可替尼组合物及其用途
FR3128874B1 (fr) * 2021-11-09 2025-04-18 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
CA3242322A1 (fr) 2021-12-28 2023-07-06 Arcutis Biotherapeutics, Inc. Mousses aerosols topiques de roflumilast
EP4233837A1 (fr) * 2022-02-24 2023-08-30 CellAct Pharma GmbH Compositions solides et orales de toniribate d'étoposide
CN119300828A (zh) 2022-05-16 2025-01-10 美国阿卡斯蒂制药股份有限公司 尼莫地平肠胃外给药
AU2023342481A1 (en) 2022-09-15 2025-04-10 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법
CN121013718A (zh) * 2023-02-03 2025-11-25 美国倍利年制药有限公司 氨氯地平冻干组合物及其用途
WO2025041069A1 (fr) * 2023-08-23 2025-02-27 Reena Patel Compositions pharmaceutiques stabilisées d'inhibiteurs de pompe à protons
US20250114388A1 (en) * 2023-10-09 2025-04-10 Dr. Anti Fungus, LLC Active pharmaceutical ingredient compositions and preparation and uses thereof
WO2025078989A1 (fr) * 2023-10-11 2025-04-17 Reena Patel Compositions pharmaceutiques stabilisées
KR20250142811A (ko) * 2024-03-22 2025-09-30 주식회사 에아스텍 노르에티스테론 에난테이트 화합물의 암의 예방 또는 치료 용도
WO2025259038A1 (fr) * 2024-06-13 2025-12-18 Chong Kun Dang Pharmaceutical Corp. Composition injectable contenant du tadalafil ou des sels pharmaceutiquement acceptables de celui-ci
CN118743693A (zh) * 2024-06-25 2024-10-08 杭州成邦医药科技有限公司 一种雷美替胺透皮贴剂及其制备方法
CN119269809B (zh) * 2024-11-27 2025-09-12 南京颐兰贝生物科技有限责任公司 一种用于定量检测雌二醇测定试剂盒
CN119499177A (zh) * 2024-11-28 2025-02-25 江苏知原药业股份有限公司 一种含有非挥发性溶剂的过氧化苯甲酰外用组合物
CN121287617A (zh) * 2025-12-10 2026-01-09 博济医药科技股份有限公司 一种氟康唑滴耳液及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
KR100382347B1 (ko) * 2000-10-30 2003-05-01 에스케이케미칼주식회사 시트상 자기발열체 및 이의 제조방법
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
US6551615B1 (en) 2001-10-18 2003-04-22 M/S. Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
CA2486280A1 (fr) * 2002-05-17 2004-04-01 New Horizons Diagnostics Corporation Identification d'une enzyme lytique associee a un phage visant a detecter et a eliminer rapidement et specifiquement bacillus anthracis
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
JP5017122B2 (ja) 2004-12-21 2012-09-05 インターベツト・インターナシヨナル・ベー・ベー 注射可能な獣医学組成物
EP1973557A4 (fr) * 2005-12-13 2010-03-03 Harkness Pharmaceuticals Inc Compositions non hygroscopiques d'enterostatine
US20110020440A1 (en) * 2007-11-19 2011-01-27 Cadila Pharmaceuticals Limited Stable solutions of sparingly soluble actives
US8128913B1 (en) * 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
WO2009128932A1 (fr) * 2008-04-15 2009-10-22 Sarcode Corporation Administration d'antagonistes de lfa-1 au système gastro-intestinal
KR101096429B1 (ko) * 2008-07-18 2011-12-20 한국유나이티드제약 주식회사 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제
US20100215726A1 (en) * 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
US9744142B2 (en) * 2009-05-05 2017-08-29 Board Of Regents, The University Of Texas Systems Formulations of volatile anesthetics and methods of use for reducing inflammation
US9364485B2 (en) * 2009-08-31 2016-06-14 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US9737478B2 (en) * 2009-09-28 2017-08-22 National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR) Treatment of malaria
CA2818891C (fr) * 2009-11-27 2016-01-19 Nuvo Research Inc. Formulations topiques d'ibuprofene
EP2575813A1 (fr) * 2010-05-28 2013-04-10 Nuvo Research Inc. Formulation topique d'étoricoxib
US8747818B1 (en) * 2011-02-07 2014-06-10 Dennis Gross Self-tanning compositions
DK2704703T3 (da) * 2011-05-03 2019-10-14 Aponia Laboratories Inc Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
WO2014001904A1 (fr) * 2012-06-27 2014-01-03 Medincell Administration de médicament biodégradable pour compositions hydrophobes

Also Published As

Publication number Publication date
SG11201508006SA (en) 2015-10-29
BR112015025172A2 (pt) 2017-07-18
CN105392469A (zh) 2016-03-09
CA2908571A1 (fr) 2014-11-06
PH12015502290A1 (en) 2016-02-01
AU2014261009A1 (en) 2015-10-29
KR101875263B1 (ko) 2018-07-05
HK1222549A1 (zh) 2017-07-07
PE20151663A1 (es) 2015-12-03
US10940205B2 (en) 2021-03-09
IN2013MU01287A (fr) 2015-05-29
JP6272454B2 (ja) 2018-01-31
PH12015502290B1 (en) 2016-02-01
US20140296191A1 (en) 2014-10-02
US20180071390A1 (en) 2018-03-15
MX2015013785A (es) 2016-08-19
CA2908571C (fr) 2018-11-06
UA119324C2 (uk) 2019-06-10
KR20170110728A (ko) 2017-10-11
US9827315B2 (en) 2017-11-28
JP2016515609A (ja) 2016-05-30
KR20150126067A (ko) 2015-11-10
WO2014178065A1 (fr) 2014-11-06
SA515361262B1 (ar) 2018-08-18
AU2014261009B2 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
MA38544A1 (fr) Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
JP7160433B2 (ja) ロキソプロフェン配合皮膚用外用剤
WO2017208072A3 (fr) Compositions nasales à base de cannabidiol
MA32027B1 (fr) Preparation de capsules
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
MA34525B1 (fr) Nouveau conjugué de facteur de croissance hématopoïétique g-csf et de polyéthylène glycol
MY160652A (en) Pharmaceutical composition for oral administration
Micewicz et al. Identification of novel small-molecule inhibitors of Zika virus infection
Sengel-Turk et al. Nanosized drug carriers for oral delivery of anticancer compounds and the importance of the chromatographic techniques
JP2017200909A (ja) ロキソプロフェン配合皮膚用外用剤
JP2017506241A (ja) ウコンならびにホソババレンギクの抽出物を含有する、末梢性炎症ならびに疼痛の軽減に有用な組成物
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
AR056471A1 (es) Formulaciones de acetato de bazedoxifeno
JP2020011903A (ja) 外用組成物
BR0317523A (pt) Processo para a preparação de formulações farmacêuticas de combinação utilizando fluidos supercrìticos
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
JP2020002060A (ja) 外用組成物
JP2003306430A (ja) 皮膚外用剤組成物
BRPI0514611A (pt) uso de um composto, compostos, e, medicamento
TW201143812A (en) Aqueous composition to be contained in container
JP7809465B2 (ja) ロキソプロフェンを含有する外用塗布剤
JP5513827B2 (ja) 外用医薬組成物
RU2024132533A (ru) Противораковый состав, содержащий пентаборат натрия, куркумин и пиперин, для применения для лечения печеночно-клеточной карциномы